A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
Phase 2
Completed
- Conditions
- Androgenetic Alopecia
- Interventions
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Intrepid Therapeutics, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT02279823
- Locations
- 🇺🇸
DermResearch, Inc., Austin, Texas, United States
🇺🇸Therapeutics Clinical Research, San Diego, California, United States
🇺🇸Minnesota Clinical Study Center, Fridley, Minnesota, United States
An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Intrepid Therapeutics, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT01831960
- Locations
- 🇺🇸
Shideler Clinical Research Center, Carmel, Indiana, United States
🇺🇸Michigan Center for Research Corp., Clinton Township, Michigan, United States
🇺🇸Northwest Clinical Trials, Inc., Boise, Idaho, United States
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- Intrepid Therapeutics, Inc.
- Target Recruit Count
- 363
- Registration Number
- NCT01631474
- Locations
- 🇺🇸
Dermatology Research Associates, Los Angeles, California, United States
🇺🇸Marina I. Peredo, M.D., PC, Smithtown, New York, United States
🇺🇸Clinical Partners, LLC, Johnston, Rhode Island, United States
© Copyright 2025. All Rights Reserved by MedPath